Latest Contrast Nephropathy News
AKI occurred with similar frequency among patients who did and did not receive contrast medium.
Myocardial infarction patients who underwent percutaneous coronary intervention had an AKI rate similar to those who did not have the procedure.
Risk factors include impaired renal function and inadequate hydration prior to contrast exposure.
Compared with control treatment, RenalGuard therapy correlated with significantly reduced CI-AKI, as well as a reduced need for renal replacement therapy.
In a study, the odds of acute kidney injury were 7% lower among patients who received radiocontrast versus those who did not.
CIN developed in 14.7% of patients with low hemoglobin levels compared with 5% of those with normal levels.
N-acetylcysteine patients had significantly decreased odds of contrast-induced nephropathy.
CARIN trial reported no significant differences in acute kidney injury incidence between novel compound CMX-2043 and placebo.
Greatest reduction for N-acetylcysteine in patients receiving low-osmolar contrast media.
Risk is linked to small changes in serum creatinine and eGFR on the day after contrast exposure.
Reduced risk of contrast-induced nephropathy with no increase in acute heart failure.
Study reveals a 13% incidence of CIN in allograft recipients undergoing computed tomography or cardiac catheterization with contrast media.
Contrast-Induced Nephropathy is significantly associated with mortality and need for dialysis; hydration is also a predictor of CIN.
Increased long-term mortality risk for patients with, but not those without, chronic kidney disease.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)
Renal and Urology News Articles
- Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
- Pruritus in Hemodialysis Patients Underestimated, Undertreated
- Anagliptin Improves LDL Partly Via ApoB-100 Suppression
- First Metastasis Site Predicts Prostate Cancer-Specific Survival
- High Phosphorus Ups Risk of Kidney Transplant Failure, Death